| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.77B | 5.77 | 59.36 | 43.5% | 9.32% | 1.85% | ||
| CORTCorcept Therapeutics Incorporated | 3.93B | 37.36 | 30.37 | 39.94% | 14.19% | 16.65% | 4.98% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 306.74M | 2.00 | -1.23 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 428.81M | 1.18 | -1.87 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 232.75M | 2.51 | -2.56 | -52.45% | 0.01 | |||
| BIOABioAge Labs, Inc. | 640.01M | 17.85 | -2.69 | -12.81% | -27.32% | 0.03 | ||
| MISTMilestone Pharmaceuticals Inc. | 166.93M | 1.96 | -2.93 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 422.59M | 4.05 | -3.02 | -95.31% | -4195.75% | -45.21% | 0.01 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 39.97M | 48.4M | 78.19M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 30.52M | 33.89M | 59.04M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 |
| Operating Income | -39.97M | -48.4M | -78.19M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -0.21% | -0.62% |
| EBITDA | -39.84M | -48.24M | -78.03M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -0.21% | -0.62% |
| D&A (Non-Cash Add-back) | 129K | 162K | 167K |
| EBIT | -39.48M | -56.06M | -68.74M |
| Net Interest Income | 224K | -5.36M | 7.26M |
| Interest Income | 465K | 2.43M | 9.63M |
| Interest Expense | 241K | 7.79M | 2.37M |
| Other Income/Expense | 247K | -15.45M | 7.08M |
| Pretax Income | -39.72M | -63.85M | -71.11M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -39.72M | -63.85M | -71.11M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -0.61% | -0.11% |
| Net Income (Continuing) | -39.72M | -63.85M | -71.11M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -5.32 | -8.55 | -6.63 |
| EPS Growth % | - | -0.61% | 0.22% |
| EPS (Basic) | -5.32 | -8.55 | -6.63 |
| Diluted Shares Outstanding | 7.46M | 7.47M | 10.73M |
| Basic Shares Outstanding | 7.46M | 7.47M | 10.73M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 28.03M | 25.31M | 357.1M |
| Cash & Short-Term Investments | 27.64M | 21.64M | 354.35M |
| Cash Only | 27.64M | 21.64M | 354.35M |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 386K | 3.66M | 2.75M |
| Total Non-Current Assets | 399K | 618K | 1.13M |
| Property, Plant & Equipment | 374K | 518K | 791K |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 100K | 100K |
| Other Non-Current Assets | 25K | 0 | 240K |
| Total Assets | 28.43M | 25.92M | 358.23M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | -0.09% | 12.82% |
| Total Current Liabilities | 5.86M | 58.17M | 27.77M |
| Accounts Payable | 2.26M | 1.87M | 2M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 167K | 44.86M | 6M |
| Deferred Revenue (Current) | 0 | 1000K | 1000K |
| Other Current Liabilities | 24K | 1.39M | 417K |
| Current Ratio | 4.78x | 0.44x | 12.86x |
| Quick Ratio | 4.78x | 0.44x | 12.86x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 135.13M | 141.15M | 7.33M |
| Long-Term Debt | 2.25M | 8.2M | 2.5M |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 132.88M | 132.95M | 156K |
| Total Liabilities | 140.99M | 199.32M | 35.11M |
| Total Debt | 2.47M | 53.25M | 8.7M |
| Net Debt | -25.18M | 31.61M | -345.64M |
| Debt / Equity | - | - | 0.03x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -165.85x | -6.21x | -33.04x |
| Total Equity | -112.56M | -173.4M | 323.13M |
| Equity Growth % | - | -0.54% | 2.86% |
| Book Value per Share | -15.09 | -23.23 | 30.12 |
| Total Shareholders' Equity | -112.56M | -173.4M | 323.13M |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -117.85M | -181.7M | -252.81M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 167K | 164K | 245K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -36.18M | -37.36M | -51.52M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | -0.03% | -0.38% |
| Net Income | -39.72M | -63.85M | -71.11M |
| Depreciation & Amortization | 129K | 162K | 167K |
| Stock-Based Compensation | 2.54M | 3.02M | 6.98M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 77K | 16.6M | 1.26M |
| Working Capital Changes | 795K | 6.71M | 11.18M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 994K | -393K | 6K |
| Cash from Investing | -103K | -266K | -366K |
| Capital Expenditures | -103K | -166K | -366K |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 2.5M | 34.94M | 381.2M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | -1K | -59K | -4.42M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -36.28M | -37.53M | -51.89M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -0.03% | -0.38% |
| FCF per Share | -4.86 | -5.03 | -4.84 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.59x | 0.72x |
| Interest Paid | 129K | 1.16M | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -94.98% |
| Debt / Equity | - | - | 0.03x |
| Interest Coverage | -165.85x | -6.21x | -33.04x |
| FCF Conversion | 0.91x | 0.59x | 0.72x |
BioAge Labs, Inc. (BIOA) reported $5.9M in revenue for fiscal year 2024.
BioAge Labs, Inc. (BIOA) grew revenue by 0.0% over the past year. Growth has been modest.
BioAge Labs, Inc. (BIOA) reported a net loss of $75.8M for fiscal year 2024.
BioAge Labs, Inc. (BIOA) has a return on equity (ROE) of -95.0%. Negative ROE indicates the company is unprofitable.
BioAge Labs, Inc. (BIOA) had negative free cash flow of $59.1M in fiscal year 2024, likely due to heavy capital investments.